Add to favorites

#Industry News

YINGCHI TMS has received new FDA granted clearances for two major treatment indications

We are thrilled to announce that YINGCHI TMS has received new FDA granted clearances for two major treatment indications

✔ YINGCHI rTMS for Obsessive-Compulsive Disorder (OCD) – K243459

✔ Intermittent Theta Burst Stimulation (iTBS) for Major Depressive Disorder – K243460

So far, YINGCHI TMS has been approved by FDA for rTMS treating OCD, rTMS treating MDD, and iTBS for MDD.

These FDA clearances solidify the trust that healthcare providers, patients, and partners place in our technology to deliver consistent, reliable results. We will continue to innovate and collaborate with healthcare professionals to deliver cutting-edge solutions that transform lives.

Details

  • Shenzhen, Guangdong Province, China
  • Shenzhen Yingchi Technology